Donovan Joanne M. - Jan 28, 2025 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)

Role
CMO
Signature
John R. Moore Attorney-in-Fact for Donovan Joanne M.
Stock symbol
EWTX
Transactions as of
Jan 28, 2025
Transactions value $
-$513,658
Form type
4
Date filed
1/30/2025, 04:05 PM
Previous filing
Sep 24, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EWTX Common Stock Options Exercise $177K +25K +152.83% $7.08 41.4K Jan 28, 2025 Direct F1, F2
transaction EWTX Common Stock Sale -$691K -25K -60.45% $27.63 16.4K Jan 28, 2025 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EWTX Stock Option (Right to Buy) Options Exercise $0 -25K -12.5% $0.00 175K Jan 28, 2025 Common Stock 25K $7.08 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 30, 2024.
F2 Includes 1,820 shares purchased on November 15, 2024 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.
F3 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $27.09 to $27.96, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 1/48th of the shares subject to the option vest each month beginning on September 17, 2023, subject to the Reporting Person continuing as a service provider through each vest date.